Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial.
COVID-19
Efficacy
Hydroxychloroquine
Outcomes
Safety
Treatment
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Dec 2021
06 Dec 2021
Historique:
received:
08
05
2021
accepted:
22
11
2021
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Several repurposed drugs such as hydroxychloroquine (HCQ) have been investigated for treatment of COVID-19, but none was confirmed to be efficacious. While in vitro studies have demonstrated antiviral properties of HCQ, data from clinical trials were conflicting regarding its benefit for COVID-19 treatment. Drugs that limit viral replication may be beneficial in the earlier course of the disease thus slowing progression to severe and critical illness. We conducted a randomized open label Phase II clinical trial from October-December 2020. Patients diagnosed with COVID-19 using RT-PCR were included in the study if they were 18 years and above and had a diagnosis of COVID-19 made in the last 3 days. Patients were randomized in blocks, to receive either HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment or SOC treatment alone. SARS COV-2 viral load (CT values) from RT-PCR testing of samples collected using nasal/orapharyngeal swabs was performed at baseline, day 2, 4, 6, 8 and 10. The primary outcome was median time from randomization to SARS COV-2 viral clearance by day 6. Of the 105 participants enrolled, 55 were assigned to the intervention group (HCQ plus SOC) and 50 to the control group (SOC only). Baseline characteristics were similar across treatment arms. Viral clearance did not differ by treatment arm, 20 and 19 participants respectively had SARS COV-2 viral load clearance by day 6 with no significant difference, median (IQR) number of days to viral load clearance between the two groups was 4(3-4) vs 4(2-4): p = 0.457. There were no significant differences in secondary outcomes (symptom resolution and adverse events) between the intervention group and the control group. There were no significant differences in specific adverse events such as elevated alkaline phosphatase, prolonged QTc interval on ECG, among patients in the intervention group as compared to the control group. Our results show that HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days was safe but not associated with reduction in viral clearance or symptom resolution among adults with COVID-19 in Uganda. NCT04860284.
Sections du résumé
BACKGROUND
BACKGROUND
Several repurposed drugs such as hydroxychloroquine (HCQ) have been investigated for treatment of COVID-19, but none was confirmed to be efficacious. While in vitro studies have demonstrated antiviral properties of HCQ, data from clinical trials were conflicting regarding its benefit for COVID-19 treatment. Drugs that limit viral replication may be beneficial in the earlier course of the disease thus slowing progression to severe and critical illness.
DESIGN
METHODS
We conducted a randomized open label Phase II clinical trial from October-December 2020.
METHODS
METHODS
Patients diagnosed with COVID-19 using RT-PCR were included in the study if they were 18 years and above and had a diagnosis of COVID-19 made in the last 3 days. Patients were randomized in blocks, to receive either HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment or SOC treatment alone. SARS COV-2 viral load (CT values) from RT-PCR testing of samples collected using nasal/orapharyngeal swabs was performed at baseline, day 2, 4, 6, 8 and 10. The primary outcome was median time from randomization to SARS COV-2 viral clearance by day 6.
RESULTS
RESULTS
Of the 105 participants enrolled, 55 were assigned to the intervention group (HCQ plus SOC) and 50 to the control group (SOC only). Baseline characteristics were similar across treatment arms. Viral clearance did not differ by treatment arm, 20 and 19 participants respectively had SARS COV-2 viral load clearance by day 6 with no significant difference, median (IQR) number of days to viral load clearance between the two groups was 4(3-4) vs 4(2-4): p = 0.457. There were no significant differences in secondary outcomes (symptom resolution and adverse events) between the intervention group and the control group. There were no significant differences in specific adverse events such as elevated alkaline phosphatase, prolonged QTc interval on ECG, among patients in the intervention group as compared to the control group.
CONCLUSION
CONCLUSIONS
Our results show that HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days was safe but not associated with reduction in viral clearance or symptom resolution among adults with COVID-19 in Uganda.
TRIAL REGISTRATION
BACKGROUND
NCT04860284.
Identifiants
pubmed: 34872511
doi: 10.1186/s12879-021-06897-9
pii: 10.1186/s12879-021-06897-9
pmc: PMC8647506
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Banques de données
ClinicalTrials.gov
['NCT04860284']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1218Informations de copyright
© 2021. The Author(s).
Références
Drugs Ther Perspect. 2020 Aug 9;:1-3
pubmed: 32837195
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219
pubmed: 32391667
Int J Antimicrob Agents. 2020 May;55(5):105960
pubmed: 32251731
J Infect Dis. 2016 Dec 15;214(12):1831-1839
pubmed: 27923947
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Sci Rep. 2020 Dec 17;10(1):22139
pubmed: 33335141
Int J Infect Dis. 2020 Jul;96:61-67
pubmed: 32339722
Clin Microbiol Infect. 2021 Jan;27(1):19-27
pubmed: 32860962
N Engl J Med. 2021 Feb 4;384(5):417-427
pubmed: 33289973
Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8
pubmed: 15351731
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965
pubmed: 33037151
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
J Antimicrob Chemother. 2015;70(6):1608-21
pubmed: 25693996
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
Medicine (Baltimore). 2020 Dec 24;99(52):e23720
pubmed: 33350752
EClinicalMedicine. 2020 Dec;29:100645
pubmed: 33251500
J Antimicrob Chemother. 2021 Jan 1;76(1):30-42
pubmed: 33031488
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Ann Intern Med. 2021 Mar;174(3):344-352
pubmed: 33284679
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
pubmed: 24841269
Nature. 2020 Sep;585(7826):584-587
pubmed: 32698191
Clin Infect Dis. 2021 Jun 1;72(11):e835-e843
pubmed: 33068425
Cochrane Database Syst Rev. 2021 Feb 12;2:CD013587
pubmed: 33624299
JAMA Intern Med. 2021 Feb 1;181(2):195-202
pubmed: 33001138
Immunopharmacol Immunotoxicol. 2013 Jun;35(3):434-42
pubmed: 23635029
BMJ Open Respir Res. 2020 Sep;7(1):
pubmed: 32900781
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
J Rheumatol. 2017 Mar;44(3):398
pubmed: 28250164
Int J Antimicrob Agents. 2020 Dec;56(6):106224
pubmed: 33166694